Shares of Cumberland Pharmaceuticals Inc. (CPIX) are up over 20% in premarket hours today, following positive top-line results from its Phase 2 FIGHT DMD trial.
The FIGHT DMD trial is a phase II study evaluating Ifetroban, a novel oral therapy, targeting cardiac complications in Duchenne muscular dystrophy or DMD patients. The primary endpoint of the trial was an improvement in the heart's left ventricular ejection fractions.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com